A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas.
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Enzastaurin (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 09 Apr 2018 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2018.
- 01 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.